Newsroom
The Latest News From the Ivy Center
The Ivy Brain Tumor Center at Barrow Neurological Institute strives to be a valuable resource for any brain tumor or brain cancer-related media needs. Our media relations team is happy to help answer questions and arrange interviews. The expert neurosurgeons, neuro-oncologists and scientists at the Ivy Center are available to speak on a variety of topics.
Our state-of-the-art media studio is available for audio and video interviews. We can also arrange filming opportunities at various locations around the center and labs.
To contact the media relation team, call Jennifer Keeler at 602-670-4400 or email: [email protected].
Please see below for the latest media coverage and news from the Ivy Center. To read about our inspiring patients and those behind the scenes at the Ivy Center, visit the Ivy Blog.
Understanding Brain Tumors
BrainWise recently featured the Ivy Brain Tumor Center in the article "Understanding Brain Tumors," where Dr. Yoshie Umemura, Chief of Neuro-Oncology at Barrow Neurological Institute and Chief Medical Officer at the Ivy Center, discusses the differences between primary and secondary brain tumors. Read more!
Ivy Brain Tumor Center announces dosing of first subject in glioblastoma trial
Clinical Trials Arena spotlighted the Ivy Brain Tumor Center at Barrow Neurological Institute, which has begun the Phase III Gliofocus trial of niraparib for recently diagnosed MGMT-unmethylated glioblastoma. Supported by GSK, the trial will involve 450 subjects across over 100 sites in 11 countries. Positive data from earlier trials led to this advancement. The study will compare niraparib’s efficacy to the standard chemotherapy, temozolomide. Dr. Nader Sanai, Director of the Ivy Center, highlighted the trial's potential to improve glioblastoma treatment outcomes.
First patient dosed in Phase 3 Gliofocus Study for newly diagnosed glioblastoma patients at the Ivy Brain Tumor Center
The Ivy Brain Tumor Center announced that the first patient has been dosed in the pivotal Phase 3 Gliofocus Study. Gliofocus is an open-label, randomized Phase 3 trial that will compare the efficacy of niraparib, a PARP1/2 selective inhibitor, to temozolomide head-to-head in adult patients with newly diagnosed MGMT-unmethylated glioblastoma.
Valley woman spreading awareness about brain tumors
Channel 12News recently featured Marie Donahue, a dedicated U.S. Navy member and patient at the Ivy Brain Tumor Center, in honor of Brain Tumor Awareness Month. Despite facing a daunting brain tumor diagnosis, Marie has tackled every day with an adventurous spirit and a renewed outlook on life. Watch her inspiring story now!
ASCO24: A roundup of the latest data from Merus, MorphoSys and others
Endpoints News featured The Ivy Brain Tumor Center’s Phase 0/2 study of niraparib, GSK’s PARP inhibitor, in newly diagnosed glioblastoma patients. This study had promising results and has led the Ivy Brain Tumor Center and GSK to collaborate on a Phase 3 study of niraparib versus temozolomide in MGMT-unmethylated glioblastoma. Read more!
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
The Ivy Brain Tumor Center has released promising Phase 0/2 clinical trial results for niraparib, showing a significant improvement in overall survival for newly diagnosed glioblastoma patients, with survival times nearly doubling to 20.3 months compared to standard care. These findings will be presented at the 2024 ASCO Annual Meeting. Encouraged by these results, GSK is supporting the initiation of a global Phase 3 trial to further evaluate niraparib versus standard care.
‘Dine & Donate’ supports brain tumor research across Phoenix-area
Good Morning Arizona spotlighted the Ivy Brain Tumor Center at Barrow Neurological Institute in recognition of Brain Tumor Awareness Month. As part of this initiative, Cold Beer and Cheeseburgers has teamed up with the Ivy Center for their annual Dine & Donate campaign. This partnership plays a crucial role in advancing vital research efforts aimed at combating brain tumors. Learn more about how you can support this important cause.
2024 Health-Care Heroes
Phoenix Magazine has recognized Jacki Garcia, Nurse Educator at the Ivy Brain Tumor Center, as a 2024 Healthcare Hero. Jacki has played a crucial role in supporting our brain tumor patients through their brain cancer journeys with profound compassion and empathy.
AstraZeneca’s ATM Inhibitor, Radiation Show Encouraging Signals in Two Early Brain Cancer Trials
Precision Medicine Online's article covered the Ivy Center's groundbreaking findings at the American Association for Cancer Research's annual meeting. Dr. Sanai's Phase 0/1 trial demonstrated the efficacy of AstraZeneca's AZD1390 in treating glioblastoma. These findings offer new hope for patients with limited treatment options. Learn more!
AstraZeneca’s ‘radiosensitizer’ may enhance efficacy of radiation for deadly brain cancer: #AACR24
Endpoints News highlighted Dr. Nader Sanai’s groundbreaking research with AstraZeneca's AZD1390 in glioblastoma treatment at AACR 2024. The Phase 0 study, led by Dr. Sanai, Director of the Ivy Brain Tumor Center, demonstrates the drug's efficacy in penetrating brain tissue—a pivotal advancement in glioblastoma therapy. Learn more!